gavi.org
Personalized mRNA Cancer Vaccine Shows Success in Phase 3 Melanoma Trial
A personalized mRNA cancer vaccine, developed by Moderna and Merck, significantly reduced the risk of recurrence and spread of high-risk melanoma in a large-scale Phase 3 clinical trial. This breakthr